Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Sell
33
NMTC Quote, Financials, Valuation and Earnings
Last price:
$1.01
Seasonality move
:
-26.1%
Day range:
$0.99 - $1.04
52-week range:
$0.55 - $1.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.08x
P/B ratio:
10.78x
Volume:
202.7K
Avg. volume:
194K
1-year change:
-7.66%
Market cap:
$31.6M
Revenue:
$3.5M
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
-- | -- | 157.41% | -57.14% | -- |
|
NTRB
Nutriband
|
$710K | -$0.13 | -- | -- | $13.00 |
|
NVNO
enVVeno Medical
|
$400K | -$0.30 | -- | -26.67% | $16.50 |
|
SINT
SINTX Technologies
|
$574K | -$5.29 | 20.07% | -96.14% | $300.00 |
|
XAIR
Beyond Air
|
$929.6K | -- | 195.4% | -- | $2.25 |
|
ZBH
Zimmer Biomet Holdings
|
$2B | $2.29 | 0.27% | 110.78% | $121.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$1.03 | -- | $31.6M | -- | $0.00 | 0% | 5.08x |
|
NTRB
Nutriband
|
$6.73 | $13.00 | $74.7M | -- | $0.00 | 0% | 32.99x |
|
NVNO
enVVeno Medical
|
$2.98 | $16.50 | $52.3M | -- | $0.00 | 0% | 273.57x |
|
SINT
SINTX Technologies
|
$3.00 | $300.00 | $8.4M | -- | $0.00 | 0% | 1.87x |
|
XAIR
Beyond Air
|
$0.27 | $2.25 | $23.7M | -- | $0.00 | 0% | 4.84x |
|
ZBH
Zimmer Biomet Holdings
|
$110.73 | $121.85 | $22B | 24.88x | $0.24 | 0.87% | 2.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
-- | -2.513 | -- | 2.23x |
|
NTRB
Nutriband
|
1.68% | 4.975 | 0.28% | 4.65x |
|
NVNO
enVVeno Medical
|
-- | -0.506 | -- | -- |
|
SINT
SINTX Technologies
|
0.82% | -1.062 | 0.68% | 1.91x |
|
XAIR
Beyond Air
|
0.34% | 1.443 | 0.22% | 2.15x |
|
ZBH
Zimmer Biomet Holdings
|
33.23% | 0.939 | 29.49% | 0.82x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$1.9M | $1.7M | -238.93% | -238.93% | 64.45% | $183.6K |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
NVNO
enVVeno Medical
|
-- | -$6.7M | -- | -- | -- | -$5.1M |
|
SINT
SINTX Technologies
|
$38K | -$1.6M | -146.19% | -148.9% | -875.52% | -$1.3M |
|
XAIR
Beyond Air
|
-$215K | -$11M | -151.32% | -225.36% | -1192.54% | -$8.3M |
|
ZBH
Zimmer Biomet Holdings
|
$1.4B | $423.5M | 4.87% | 7.21% | 17.34% | $421.4M |
NeuroOne Medical Technologies vs. Competitors
-
Which has Higher Returns NMTC or NTRB?
Nutriband has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -211%. NeuroOne Medical Technologies's return on equity of -238.93% beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About NMTC or NTRB?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 95.12%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 93.17%. Given that NeuroOne Medical Technologies has higher upside potential than Nutriband, analysts believe NeuroOne Medical Technologies is more attractive than Nutriband.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 NTRBNutriband1 0 0 -
Is NMTC or NTRB More Risky?
NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison Nutriband has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.457%.
-
Which is a Better Dividend Stock NMTC or NTRB?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NTRB?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Nutriband quarterly revenues of $645.8K. NeuroOne Medical Technologies's net income of $1.8M is higher than Nutriband's net income of -$1.4M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.08x versus 32.99x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.08x -- $3.3M $1.8M NTRBNutriband32.99x -- $645.8K -$1.4M
-
Which has Higher Returns NMTC or NVNO?
enVVeno Medical has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of --. NeuroOne Medical Technologies's return on equity of -238.93% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M NVNOenVVeno Medical-- -$0.30 -- -
What do Analysts Say About NMTC or NVNO?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 95.12%. On the other hand enVVeno Medical has an analysts' consensus of $16.50 which suggests that it could grow by 453.69%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 NVNOenVVeno Medical1 0 0 -
Is NMTC or NVNO More Risky?
NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.377, suggesting its more volatile than the S&P 500 by 37.658%.
-
Which is a Better Dividend Stock NMTC or NVNO?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NVNO?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than enVVeno Medical quarterly revenues of --. NeuroOne Medical Technologies's net income of $1.8M is higher than enVVeno Medical's net income of -$6.2M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.08x versus 273.57x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.08x -- $3.3M $1.8M NVNOenVVeno Medical273.57x -- -- -$6.2M
-
Which has Higher Returns NMTC or SINT?
SINTX Technologies has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -882.81%. NeuroOne Medical Technologies's return on equity of -238.93% beat SINTX Technologies's return on equity of -148.9%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M SINTSINTX Technologies19.79% -$1.26 $3.9M -
What do Analysts Say About NMTC or SINT?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 95.12%. On the other hand SINTX Technologies has an analysts' consensus of $300.00 which suggests that it could grow by 2233.33%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 SINTSINTX Technologies0 1 0 -
Is NMTC or SINT More Risky?
NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.201, suggesting its more volatile than the S&P 500 by 20.05%.
-
Which is a Better Dividend Stock NMTC or SINT?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or SINT?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than SINTX Technologies quarterly revenues of $192K. NeuroOne Medical Technologies's net income of $1.8M is higher than SINTX Technologies's net income of -$1.7M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.08x versus 1.87x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.08x -- $3.3M $1.8M SINTSINTX Technologies1.87x -- $192K -$1.7M
-
Which has Higher Returns NMTC or XAIR?
Beyond Air has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -1215.67%. NeuroOne Medical Technologies's return on equity of -238.93% beat Beyond Air's return on equity of -225.36%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M XAIRBeyond Air-20.06% -$0.15 $18.4M -
What do Analysts Say About NMTC or XAIR?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 95.12%. On the other hand Beyond Air has an analysts' consensus of $2.25 which suggests that it could grow by 738.93%. Given that Beyond Air has higher upside potential than NeuroOne Medical Technologies, analysts believe Beyond Air is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 XAIRBeyond Air1 1 0 -
Is NMTC or XAIR More Risky?
NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison Beyond Air has a beta of 0.160, suggesting its less volatile than the S&P 500 by 83.96%.
-
Which is a Better Dividend Stock NMTC or XAIR?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or XAIR?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Beyond Air quarterly revenues of $1.1M. NeuroOne Medical Technologies's net income of $1.8M is higher than Beyond Air's net income of -$13M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.08x versus 4.84x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.08x -- $3.3M $1.8M XAIRBeyond Air4.84x -- $1.1M -$13M
-
Which has Higher Returns NMTC or ZBH?
Zimmer Biomet Holdings has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of 11.84%. NeuroOne Medical Technologies's return on equity of -238.93% beat Zimmer Biomet Holdings's return on equity of 7.21%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M ZBHZimmer Biomet Holdings71% $1.20 $18.7B -
What do Analysts Say About NMTC or ZBH?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 95.12%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $121.85 which suggests that it could grow by 10.04%. Given that NeuroOne Medical Technologies has higher upside potential than Zimmer Biomet Holdings, analysts believe NeuroOne Medical Technologies is more attractive than Zimmer Biomet Holdings.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 ZBHZimmer Biomet Holdings5 17 1 -
Is NMTC or ZBH More Risky?
NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.696%.
-
Which is a Better Dividend Stock NMTC or ZBH?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 0.87% to investors and pays a quarterly dividend of $0.24 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NMTC or ZBH?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are smaller than Zimmer Biomet Holdings quarterly revenues of $2B. NeuroOne Medical Technologies's net income of $1.8M is lower than Zimmer Biomet Holdings's net income of $239.5M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Zimmer Biomet Holdings's PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.08x versus 2.94x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.08x -- $3.3M $1.8M ZBHZimmer Biomet Holdings2.94x 24.88x $2B $239.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
